Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 1998
Business Overview: Myriad is a biotechnology company focused on discovering genes related to major common diseases (cancer, cardiovascular disease) and developing genetic testing services. Key commercial products include the BRACAnalysis(TM) test for breast/ovarian cancer susceptibility and the CardiaRisk(TM) test for cardiovascular risk. The company relies heavily on strategic alliances with pharmaceutical partners (Schering, Novartis, Bayer, Eli Lilly) for research funding and therapeutic development.
Key Financial Metrics
| Metric | Fiscal Year 1998 | Fiscal Year 1997 |
|---|---|---|
| Total Revenues | $23,210,581 | $15,236,099 |
| Research Revenue | $20,999,598 | $14,732,054 |
| Genetic Testing Revenue | $2,210,983 | $504,045 |
| Operating Loss | $(12,990,150) | $(12,439,808) |
| Net Loss | $(9,797,035) | $(9,206,280) |
| Net Loss Per Share | $(1.05) | $(1.03) |
| Cash & Cash Equivalents | $14,595,034 | $24,075,763 |
| Total Assets | $67,391,972 | $76,063,331 |
| Working Capital | $21,806,290 | $38,796,960 |
| Notes Payable (Long-term) | $0 | $128,844 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 52% to $23.2 million, driven by a 42% increase in research revenue and a 339% surge in genetic testing revenue.
- Research Milestones: The company recognized $3.0 million in milestone payments during the year ($2.5 million from Schering for the MMAC1 gene discovery and $0.5 million from Novartis for the CHD1 gene discovery).
- Expense Increases: Research and development expenses rose 24% to $23.0 million due to expanded collaborations and equipment purchases. Selling, general, and administrative (SG&A) expenses increased 35% to $11.8 million, primarily due to the expansion of the sales force (from 8 to 33 employees) and legal defense costs.
- Liquidity: Cash and cash equivalents decreased by approximately $9.5 million, though the company maintains a strong balance sheet with over $53 million in total cash and marketable securities.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur losses for at least the next several years due to continued expansion of R&D, staffing, and facilities. The company anticipates that existing capital resources will be adequate for at least the next two years.
- Strategic Milestones: Successfully launched CardiaRisk(TM) in January 1998. Expanded the alliance with Bayer to include central nervous system disorders, with potential funding up to $54 million.
- Legal Contingencies: The company settled patent infringement litigation with OncorMed, Inc. in May 1998, dismissing all pending actions. No other material legal proceedings are currently pending.
- Key Risks:
- Regulatory: Uncertainty regarding FDA regulation of genetic tests currently performed in-house; potential requirement for FDA approval could delay or halt testing services.
- Reimbursement: Success of the testing business depends on third-party payors (insurance) reimbursing for genetic tests.
- Competition: Intense competition from pharmaceutical companies and academic institutions with greater resources.
- Year 2000 Issue: Management believes the Y2K issue will not have a material effect, but acknowledges potential operational disruptions if suppliers or customers fail to comply.
Investor Verification Checklist
- Revenue Sustainability: Verify the proportion of revenue derived from milestone payments versus recurring research funding and testing fees.
- Reimbursement Status: Confirm the current status of third-party insurance reimbursement for BRACAnalysis(TM) and CardiaRisk(TM) tests.
- Regulatory Environment: Monitor FDA statements regarding the regulation of laboratory-developed genetic tests.
- Patent Portfolio: Review the status of the settlement with OncorMed and the strength of patents covering BRCA1, BRCA2, and other discovered genes.
- Cash Burn Rate: Assess whether the current cash position ($53M+) is sufficient to fund operations until profitability or additional financing is secured, given the projected continued losses.